CAS 2023788-19-2

Tirzepatide

Descrizione:

Tirzepatide è un nuovo peptide sintetico che funge da agonista dual per i recettori del peptide simile al glucagone-1 (GLP-1) e del polipeptide insulinotropico dipendente dalla glucosio (GIP). È sviluppato principalmente per il trattamento del diabete di tipo 2 e dell'obesità. La sostanza è caratterizzata dalla sua struttura unica, che le consente di aumentare la secrezione di insulina in risposta ai pasti, ridurre i livelli di glucagone e promuovere la sazietà, contribuendo così al controllo glicemico e alla gestione del peso. Tirzepatide ha una lunga emivita, consentendo una somministrazione settimanale, il che migliora la compliance del paziente rispetto ai farmaci giornalieri. Il suo meccanismo d'azione implica l'imitazione degli effetti degli ormoni incretina, portando a un miglioramento del metabolismo del glucosio. Gli studi clinici hanno mostrato un'efficacia significativa nella riduzione dei livelli di zucchero nel sangue e nella promozione della perdita di peso in individui con diabete di tipo 2. Come con qualsiasi farmaco, gli effetti collaterali potenziali possono includere problemi gastrointestinali, ed è essenziale che i pazienti consultino professionisti sanitari per consigli personalizzati e monitoraggio durante il trattamento.

Formula: C225H348N48O68

InChI: InChI=1S/C225H348N48O68/c1-23-126(10)183(264-198(311)146(64-50-52-88-226)246-202(315)157(109-180(297)298)252-199(312)152(103-124(6)7)261-223(337)225(21,22)269-217(330)185(128(12)25-3)266-209(322)163(120-278)257-200(313)153(107-138-74-78-141(282)79-75-138)250-203(316)158(110-181(299)300)253-207(320)162(119-277)259-216(329)187(134(18)280)267-206(319)155(106-136-60-44-41-45-61-136)254-215(328)186(133(17)279)262-174(289)114-237-193(306)147(83-87-179(295)296)260-222(336)224(19,20)268-192(305)143(227)104-137-72-76-140(281)77-73-137)214(327)242-131(15)190(303)244-148(80-84-168(228)283)196(309)245-145(65-51-53-89-231-175(290)121-340-100-99-339-97-91-233-176(291)122-341-101-98-338-96-90-232-170(285)86-82-150(221(334)335)243-171(286)70-46-38-36-34-32-30-28-26-27-29-31-33-35-37-39-47-71-178(293)294)195(308)240-130(14)191(304)248-154(105-135-58-42-40-43-59-135)205(318)263-182(125(8)9)212(325)247-149(81-85-169(229)284)197(310)251-156(108-139-111-234-144-63-49-48-62-142(139)144)201(314)249-151(102-123(4)5)204(317)265-184(127(11)24-2)213(326)241-129(13)189(302)236-112-172(287)235-115-177(292)270-92-54-66-164(270)210(323)258-161(118-276)208(321)256-160(117-275)194(307)238-113-173(288)239-132(16)218(331)272-94-56-68-166(272)220(333)273-95-57-69-167(273)219(332)271-93-55-67-165(271)211(324)255-159(116-274)188(230)301/h40-45,48-49,58-63,72-79,111,123-134,143,145-167,182-187,234,274-282H,23-39,46-47,50-57,64-71,80-110,112-122,226-227H2,1-22H3,(H2,228,283)(H2,229,284)(H2,230,301)(H,231,290)(H,232,285)(H,233,291)(H,235,287)(H,236,302)(H,237,306)(H,238,307)(H,239,288)(H,240,308)(H,241,326)(H,242,327)(H,243,286)(H,244,303)(H,245,309)(H,246,315)(H,247,325)(H,248,304)(H,249,314)(H,250,316)(H,251,310)(H,252,312)(H,253,320)(H,254,328)(H,255,324)(H,256,321)(H,257,313)(H,258,323)(H,259,329)(H,260,336)(H,261,337)(H,262,289)(H,263,318)(H,264,311)(H,265,317)(H,266,322)(H,267,319)(H,268,305)(H,269,330)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,334,335)/t126-,127-,128-,129-,130-,131-,132-,133+,134+,143-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,182-,183-,184-,185-,186-,187-/m0/s1

InChI key: BTSOGEDATSQOAF-MCNPHUAVSA-N

SMILES: CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N

Sinonimi:

• Tianeptine  Sodium

Tirzepatide

CAS: 2023788-19-2

Formula: C₂₂₅H₃₄₈N₄₈O₆₈

Purezza: 99%

Colore e forma: Solid

Peso molecolare: 4813.4514

Ref: IN-DA01MVDA

Tirzepatide

CAS: 2023788-19-2

Formula: C₂₂₅H₃₄₈N₄₈O₆₈

Peso molecolare: 4813.53

Ref: 4Z-PT-453001

Tirzepatide sodium salt

CAS: 2023788-19-2

Formula: C₂₂₅H₃₄₈N₄₈O₆₈·Nax

Purezza: ≥ 95.0%

Colore e forma: White to off-white powder or solid

Peso molecolare: 4813.45 (ex. Na)

Ref: 7W-GP2780

Tirzepatide

CAS: 2023788-19-2

Tirzepatide (LY-3298176) is a dual glucose-dependent polypeptide (GIP) (EC50=0.042 nM) and glucagon-like peptide-1 (GLP-1) (EC50=0.086 nM) receptor agonist.

Formula: C₂₂₅H₃₄₈N₄₈O₆₈

Purezza: 99.52% - 99.99%

Colore e forma: White Solid

Peso molecolare: 4813.45

Ref: TM-TP1111

Tirzepatide

CAS: 2023788-19-2

Formula: C₂₂₅H₃₄₈N₄₈O₆₈

Colore e forma: Neat

Ref: TR-T242115

Tirzepatide sodium

CAS: 2023788-19-2

Cymit Quimica provides this product solely for uses within the scope of any statute or law providing for an immunity, exemption, or exception to patent infringement (“Exempted Uses”), including but not limited to 35 U.S.C. § 271(e)(1) in the United States, the Bolar type exemption in Europe, and any corresponding exception to patent infringement in any other country. It is the sole responsibility of the purchaser or user of this product, and the purchaser or user of this product agrees to engage only in such Exempted Uses, and to comply with all applicable intellectual property laws and/or regulations. The purchaser of this product agrees to indemnify Cymit Quimica against all claims in connection with the performance of the respective commercial agreement (e.g. supply agreement) and possible infringements of intellectual property rights.

Formula: C₂₂₅H₃₄₈N₄₈O₆₈•xNa

Purezza: Min. 95 Area-%

Colore e forma: Powder

Ref: 3D-BT183282

Tirzepatide

CAS: 2023788-19-2

Cymit Quimica provides this product solely for uses within the scope of any statute or law providing for an immunity, exemption, or exception to patent infringement (“Exempted Uses”), including but not limited to 35 U.S.C. § 271(e)(1) in the United States, the Bolar type exemption in Europe, and any corresponding exception to patent infringement in any other country. It is the sole responsibility of the purchaser or user of this product, and the purchaser or user of this product agrees to engage only in such Exempted Uses, and to comply with all applicable intellectual property laws and/or regulations. The purchaser of this product agrees to indemnify Cymit Quimica against all claims in connection with the performance of the respective commercial agreement (e.g. supply agreement) and possible infringements of intellectual property rights.

Formula: C₂₂₅H₃₄₈N₄₈O₆₈

Purezza: Min. 95%

Colore e forma: Powder

Peso molecolare: 4,813 g/mol

Ref: 3D-FT181880

Heavy Tirzepatide (+52Da)

CAS: 2023788-19-2

Heavy Tirzepatide (+52Da)

Purezza: Min. 95%

Peso molecolare: 4,862.7 g/mol

Ref: 3D-CRB1301725

Tirzepatide

CAS: 2023788-19-2

Formula: C₂₂₅H₃₄₈N₄₈O₆₈

Peso molecolare: 4813.5

Ref: ST-EA-CP-T133000

Tirzepatide acetate

CAS: 2023788-19-2

Cymit Quimica provides this product solely for uses within the scope of any statute or law providing for an immunity, exemption, or exception to patent infringement (“Exempted Uses”), including but not limited to 35 U.S.C. § 271(e)(1) in the United States, the Bolar type exemption in Europe, and any corresponding exception to patent infringement in any other country. It is the sole responsibility of the purchaser or user of this product, and the purchaser or user of this product agrees to engage only in such Exempted Uses, and to comply with all applicable intellectual property laws and/or regulations. The purchaser of this product agrees to indemnify Cymit Quimica against all claims in connection with the performance of the respective commercial agreement (e.g. supply agreement) and possible infringements of intellectual property rights.

Purezza: Min. 95%

Ref: 3D-FT182420